FridayNov 04, 2022 1:00 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Announces Full Acquisition of Interest in RKings Competitions

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of gaming platforms, systems and gaming content, has acquired the remaining 20% interest in RKings Competitions; the company now owns a total of 165,444 restricted shares of GMGI’s common stock payable to the two former owners of RKings. Company officials announced the transaction, which makes RKings a wholly owned entity of Golden Matrix, one which the company anticipates will grow quickly in several regulated jurisdictions, including Great Britain and Mexico. The company plans to expand the tournament platform into other Latin American markets in the next few years. In addition, Golden Matrix…

Continue Reading

ThursdayNov 03, 2022 12:22 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) to Participate in 13th Craig-Hallum Alpha Select Conference

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, today announced that its Chief Executive Officer Dr. Jun Pei and Chief Financial Officer Hull Xu will be participating in the 13th Craig-Hallum Alpha Select Conference. The event is slated to be held in New York City on Nov. 17, 2022. Cepton management will be available for group investor or one-on-one meetings throughout the conference. Interested parties should contact InvestorRelations@Cepton.com or their Craig-Hallum representative for related inquiries. To view the full press release, visit https://ibn.fm/kcm7E About Cepton Inc. Cepton is a Silicon Valley innovator of lidar-based solutions…

Continue Reading

ThursdayNov 03, 2022 11:13 am

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at 8:00 a.m. GMT on Nov. 15. Drysdale will also participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT on Nov. 16, 2022, at the Pinsent Masons Psychedelics Panel in London, U.K. In addition, Drysdale will participate in…

Continue Reading

ThursdayNov 03, 2022 10:00 am

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Distinctive in Highly Competitive Online Gambling Space

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, white labels its industry-leading GM-AG System that can be custom-built from 10,000+ game options for its roughly 650 clients serving about 6.8 million end users. “The online gambling space is highly competitive, leading to most of the world’s biggest operators burning through tons of cash for marketing in a bid to try and attract (and keep) customers. That’s cash that comes straight off the bottom line, explaining why many struggle to achieve profitability. That’s certainly not the case for GMGI, which continues to experience…

Continue Reading

WednesdayNov 02, 2022 2:15 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Eyes Steady Growth, Traction in Distinctive Solutions

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has grown its operations with numerous improvements to its cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. In addition, Fr8Tech is constantly exploring new ways to create value for its clients, streamline the region’s cross-border shipping process, and carry that over into respective domestic markets. Its efforts to date have yielded six distinctive solutions in its product suite: Fr8App, Fr8Radar, Fr8TMS, Fr8FMS, Fr8Data, and Fr8Fleet. A recent article reads, “The company’s focus on exploring new areas for revenue and value creation allowed for a 45% year-over-year (‘YOY’) revenue growth for…

Continue Reading

WednesdayNov 02, 2022 11:52 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing…

Continue Reading

WednesdayNov 02, 2022 10:33 am

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Eliminates Some $13M in Debt

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has eliminated $13 million in company debt, resulting in a reduction of overall indebtedness from more than $30 million last year to less than $10 million currently. The company has been working to strengthen its financial balance sheet; it also recently eliminated some $13 million of company debt associated with Esousa Holdings LLC. According to the announcement, MULN believes this debt conversion will save more than $3.5 million in interest expenses. With less than $10 million left of outstanding indebtedness, Mullen is maintaining its strong financial health. “It’s been a…

Continue Reading

TuesdayNov 01, 2022 1:35 pm

TinyGemsBreaks – Knightscope Inc. (NASDAQ: KSCP) Announces New Contracts, Indicative of Company’s Continued Reach

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced five new contracts. The contracts are with companies across the United States from several different industries. According to the announcement, the companies include an Ohio-based global pharmaceutical manufacturer and distributor of medical and laboratory products, as well as a provider of performance and data solutions for healthcare facilities; two hotels — one in Tennessee and one in Washington state; a sports complex in New York; and a multifamily housing complex in Pennsylvania. The contracts call for Knightscope ASRs to patrol and provide surveillance for everything from parking lots…

Continue Reading

TuesdayNov 01, 2022 1:23 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures IRB Approval for Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of independent review board (“IRB”) approval for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. The 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study will be conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. Only one oral nicotine pouch (either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match) will be administered during each visit and evaluated. Predetermined questionnaires for subjective…

Continue Reading

TuesdayNov 01, 2022 12:57 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

Continue Reading

Contact us: (512) 354-7000